Repligen Corporation
RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pā¦ read more
Healthcare
Medical Instruments & Supplies
40 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$141.01
Price-1.80%
-$2.59
1Y
Price
Market Cap
$7.958b
Mid
Price/Earnings 3y Avg5y Avg
78.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+16.6%
EBITDA Margin+4.3%
Net Profit Margin+12.0%
Free Cash Flow Margin+16.6%
EBITDA Margin+4.3%
Net Profit Margin+12.0%
Free Cash Flow MarginRevenue
$785.101m
+3.4%
1y CAGR+6.7%
3y CAGR-0.3%
5y CAGREarnings
$41.539m
+5.1%
1y CAGR+41.7%
3y CAGR+11.1%
5y CAGREPS
$0.73
+4.7%
1y CAGR+39.5%
3y CAGR+9.5%
5y CAGRBook Value
$2.112b
$2.950b
Assets$838.148m
Liabilities$690.942m
DebtDebt to Assets
23.4%
4x
Debt to EBITDAFree Cash Flow
$110.777m
+10.9%
1y CAGR+22.3%
3y CAGR+40.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company